- Home
- HURA vs IMMR Comparison
HURA vs IMMR Comparison
Compare HURA & IMMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURA
- IMMR
- Stock Information
- Founded
- HURA 2009
- IMMR 1993
- Country
- HURA United States
- IMMR United States
- Employees
- HURA N/A
- IMMR N/A
- Industry
- HURA
- IMMR Computer peripheral equipment
- Sector
- HURA
- IMMR Technology
- Exchange
- HURA Nasdaq
- IMMR Nasdaq
- Market Cap
- HURA 246.9M
- IMMR 272.7M
- IPO Year
- HURA N/A
- IMMR 1999
- Fundamental
- Price
- HURA $4.76
- IMMR $8.55
- Analyst Decision
- HURA Strong Buy
- IMMR Strong Buy
- Analyst Count
- HURA 1
- IMMR 1
- Target Price
- HURA $11.00
- IMMR $13.50
- AVG Volume (30 Days)
- HURA 262.4K
- IMMR 826.9K
- Earning Date
- HURA 02-15-2025
- IMMR 03-06-2025
- Dividend Yield
- HURA N/A
- IMMR 1.57%
- EPS Growth
- HURA N/A
- IMMR 57.07
- EPS
- HURA N/A
- IMMR 2.04
- Revenue
- HURA N/A
- IMMR $163,133,000.00
- Revenue This Year
- HURA N/A
- IMMR $988.71
- Revenue Next Year
- HURA N/A
- IMMR $288.32
- P/E Ratio
- HURA N/A
- IMMR $4.22
- Revenue Growth
- HURA N/A
- IMMR 338.21
- 52 Week Low
- HURA $2.84
- IMMR $6.54
- 52 Week High
- HURA $14.60
- IMMR $13.94
- Technical
- Relative Strength Index (RSI)
- HURA N/A
- IMMR 46.35
- Support Level
- HURA N/A
- IMMR $8.50
- Resistance Level
- HURA N/A
- IMMR $8.87
- Average True Range (ATR)
- HURA 0.00
- IMMR 0.39
- MACD
- HURA 0.00
- IMMR -0.02
- Stochastic Oscillator
- HURA 0.00
- IMMR 45.26
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.
About IMMR Immersion Corporation
Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.